Maximizing the erythropoietin response: Iron strategies

Mayoor V. Prabhu, Aditi Nayak, G. Sridhar, S. V. Subhramanyam, K. S. Nayak

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

Anemia is a significant cause of morbidity and lowers the quality of life of patients suffering from chronic kidney disease (CKD). Iron deficiency is the most important cause of erythropoietin (EPO) hyporesponsiveness in CKD. EPO administration significantly increases the costs of CKD management. It follows that paramount importance must be given to enhancing responsiveness to EPO thereby ensuring that the patient derives maximum benefit. Intravenous iron (IVI) administration has been used for decades to replenish body iron stores. Multiple preparations of Iron are available in the market. However, IVI administration is fraught with dangers like adverse drug reactions, susceptibility to infection, and, as recently postulated, direct cellular toxicity. Traditional approaches to IVI administration have focused on multiple administrations of lower doses for fear of adverse reactions. However, recent studies have demonstrated that higher doses can be safely administered in a single infusion, thereby reducing hospitalization costs and patient inconvenience. Newer preparations of IVI are relatively safer, easier to administer and efficacious. Preparations like Iron sucrose, ferumoxytol, ferric carboxymaltose and iron isomaltoside do not require test doses and allow higher doses to be administered at a time with cost and effect benefits.

Original languageEnglish
Title of host publicationPeritoneal Dialysis - State-of-the-Art 2012
EditorsClaudio Ronco, Carlo Crepaldi, Mitchell Rosner
PublisherS. Karger AG
Pages95-99
Number of pages5
Volume178
ISBN (Electronic)9783318021639
ISBN (Print)9783318021622
DOIs
Publication statusPublished - 30-05-2012

Publication series

NameContributions to Nephrology
Volume178
ISSN (Print)0302-5144

Fingerprint

Erythropoietin
Iron
Chronic Renal Insufficiency
Intravenous Administration
saccharated ferric oxide
Ferrosoferric Oxide
Costs and Cost Analysis
Disease Management
Drug-Related Side Effects and Adverse Reactions
Fear
Cost-Benefit Analysis
Anemia
Hospitalization
Quality of Life
Morbidity
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Prabhu, M. V., Nayak, A., Sridhar, G., Subhramanyam, S. V., & Nayak, K. S. (2012). Maximizing the erythropoietin response: Iron strategies. In C. Ronco, C. Crepaldi, & M. Rosner (Eds.), Peritoneal Dialysis - State-of-the-Art 2012 (Vol. 178, pp. 95-99). (Contributions to Nephrology; Vol. 178). S. Karger AG. https://doi.org/10.1159/000337820
Prabhu, Mayoor V. ; Nayak, Aditi ; Sridhar, G. ; Subhramanyam, S. V. ; Nayak, K. S. / Maximizing the erythropoietin response : Iron strategies. Peritoneal Dialysis - State-of-the-Art 2012. editor / Claudio Ronco ; Carlo Crepaldi ; Mitchell Rosner. Vol. 178 S. Karger AG, 2012. pp. 95-99 (Contributions to Nephrology).
@inbook{bfdf9c076d8546fb831d565327c0a6b0,
title = "Maximizing the erythropoietin response: Iron strategies",
abstract = "Anemia is a significant cause of morbidity and lowers the quality of life of patients suffering from chronic kidney disease (CKD). Iron deficiency is the most important cause of erythropoietin (EPO) hyporesponsiveness in CKD. EPO administration significantly increases the costs of CKD management. It follows that paramount importance must be given to enhancing responsiveness to EPO thereby ensuring that the patient derives maximum benefit. Intravenous iron (IVI) administration has been used for decades to replenish body iron stores. Multiple preparations of Iron are available in the market. However, IVI administration is fraught with dangers like adverse drug reactions, susceptibility to infection, and, as recently postulated, direct cellular toxicity. Traditional approaches to IVI administration have focused on multiple administrations of lower doses for fear of adverse reactions. However, recent studies have demonstrated that higher doses can be safely administered in a single infusion, thereby reducing hospitalization costs and patient inconvenience. Newer preparations of IVI are relatively safer, easier to administer and efficacious. Preparations like Iron sucrose, ferumoxytol, ferric carboxymaltose and iron isomaltoside do not require test doses and allow higher doses to be administered at a time with cost and effect benefits.",
author = "Prabhu, {Mayoor V.} and Aditi Nayak and G. Sridhar and Subhramanyam, {S. V.} and Nayak, {K. S.}",
year = "2012",
month = "5",
day = "30",
doi = "10.1159/000337820",
language = "English",
isbn = "9783318021622",
volume = "178",
series = "Contributions to Nephrology",
publisher = "S. Karger AG",
pages = "95--99",
editor = "Claudio Ronco and Carlo Crepaldi and Mitchell Rosner",
booktitle = "Peritoneal Dialysis - State-of-the-Art 2012",
address = "Switzerland",

}

Prabhu, MV, Nayak, A, Sridhar, G, Subhramanyam, SV & Nayak, KS 2012, Maximizing the erythropoietin response: Iron strategies. in C Ronco, C Crepaldi & M Rosner (eds), Peritoneal Dialysis - State-of-the-Art 2012. vol. 178, Contributions to Nephrology, vol. 178, S. Karger AG, pp. 95-99. https://doi.org/10.1159/000337820

Maximizing the erythropoietin response : Iron strategies. / Prabhu, Mayoor V.; Nayak, Aditi; Sridhar, G.; Subhramanyam, S. V.; Nayak, K. S.

Peritoneal Dialysis - State-of-the-Art 2012. ed. / Claudio Ronco; Carlo Crepaldi; Mitchell Rosner. Vol. 178 S. Karger AG, 2012. p. 95-99 (Contributions to Nephrology; Vol. 178).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Maximizing the erythropoietin response

T2 - Iron strategies

AU - Prabhu, Mayoor V.

AU - Nayak, Aditi

AU - Sridhar, G.

AU - Subhramanyam, S. V.

AU - Nayak, K. S.

PY - 2012/5/30

Y1 - 2012/5/30

N2 - Anemia is a significant cause of morbidity and lowers the quality of life of patients suffering from chronic kidney disease (CKD). Iron deficiency is the most important cause of erythropoietin (EPO) hyporesponsiveness in CKD. EPO administration significantly increases the costs of CKD management. It follows that paramount importance must be given to enhancing responsiveness to EPO thereby ensuring that the patient derives maximum benefit. Intravenous iron (IVI) administration has been used for decades to replenish body iron stores. Multiple preparations of Iron are available in the market. However, IVI administration is fraught with dangers like adverse drug reactions, susceptibility to infection, and, as recently postulated, direct cellular toxicity. Traditional approaches to IVI administration have focused on multiple administrations of lower doses for fear of adverse reactions. However, recent studies have demonstrated that higher doses can be safely administered in a single infusion, thereby reducing hospitalization costs and patient inconvenience. Newer preparations of IVI are relatively safer, easier to administer and efficacious. Preparations like Iron sucrose, ferumoxytol, ferric carboxymaltose and iron isomaltoside do not require test doses and allow higher doses to be administered at a time with cost and effect benefits.

AB - Anemia is a significant cause of morbidity and lowers the quality of life of patients suffering from chronic kidney disease (CKD). Iron deficiency is the most important cause of erythropoietin (EPO) hyporesponsiveness in CKD. EPO administration significantly increases the costs of CKD management. It follows that paramount importance must be given to enhancing responsiveness to EPO thereby ensuring that the patient derives maximum benefit. Intravenous iron (IVI) administration has been used for decades to replenish body iron stores. Multiple preparations of Iron are available in the market. However, IVI administration is fraught with dangers like adverse drug reactions, susceptibility to infection, and, as recently postulated, direct cellular toxicity. Traditional approaches to IVI administration have focused on multiple administrations of lower doses for fear of adverse reactions. However, recent studies have demonstrated that higher doses can be safely administered in a single infusion, thereby reducing hospitalization costs and patient inconvenience. Newer preparations of IVI are relatively safer, easier to administer and efficacious. Preparations like Iron sucrose, ferumoxytol, ferric carboxymaltose and iron isomaltoside do not require test doses and allow higher doses to be administered at a time with cost and effect benefits.

UR - http://www.scopus.com/inward/record.url?scp=84925795091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925795091&partnerID=8YFLogxK

U2 - 10.1159/000337820

DO - 10.1159/000337820

M3 - Chapter

C2 - 22652723

AN - SCOPUS:84862131195

SN - 9783318021622

VL - 178

T3 - Contributions to Nephrology

SP - 95

EP - 99

BT - Peritoneal Dialysis - State-of-the-Art 2012

A2 - Ronco, Claudio

A2 - Crepaldi, Carlo

A2 - Rosner, Mitchell

PB - S. Karger AG

ER -

Prabhu MV, Nayak A, Sridhar G, Subhramanyam SV, Nayak KS. Maximizing the erythropoietin response: Iron strategies. In Ronco C, Crepaldi C, Rosner M, editors, Peritoneal Dialysis - State-of-the-Art 2012. Vol. 178. S. Karger AG. 2012. p. 95-99. (Contributions to Nephrology). https://doi.org/10.1159/000337820